Organogenesis Holdings Inc.

Organogenesis is a regenerative medicine company that develops, manufactures, and sells products for the advanced wound care and surgical and sports medicine markets. The company's products aim to advance healing and recovery. Several products have Premarket Application ("PMA") approval or 510(k) clearance from the United States Food and Drug Administration ("FDA"). Organogenesis serves hospitals, wound care centers, government facilities, ambulatory surgery centers ("ASCs"), and physician offices. In the Advanced Wound Care market, Organogenesis develops and commercializes products for chronic and acute wounds. This portfolio includes Apligraf for venous leg ulcers ("VLUs") and diabetic foot ulcers ("DFUs"); Dermagraft for DFUs (manufacturing and distribution are currently suspended pending transition to a new manufacturing facility in Smithfield, RI); PuraPly AM and PuraPly XT as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold; CYGNUS Dual as a dual-layered amniotic membrane; CYGNUS Matrix as a dehydrated placental allograft; VIA Matrix, Affinity, Novachor, and NuShield placental allografts; and SimpliMax as a dehydrated amnion allograft. In the Surgical & Sports Medicine market, the company addresses chronic and acute surgical wounds and tendon and ligament injuries.